<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "mannitol inj BAG">
<dose><value>250</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>100 mg/mL</value>
<value>200 mg/mL</value>
</strength>
<frequency><value>CONTINUOUS</value>
<value>ONCE</value>
</frequency>
<instruction><value>Administer by continuous infusion.</value>
<value>DAY 1. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 8. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 1 of 21. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 1 of 28. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 8 of 28. Administer over one hour concurrently with CISplatin.</value>
</instruction>
<volume><value>1 000 mL</value>
<value>500 mL</value>
</volume>
<units><value>mL/Hour</value>
<value>mL</value>
</units>
<Population><value>Adjuvant Vinorelbine/CISplatin (every 28 days). Non-Small Cell Lung Cancer</value>
<value>Adjuvant Vinorelbine/CISplatin (every 21 days). Non-Small Cell Lung Cancer</value>
<value>Pemetrexed/CISplatin. Non-Small Cell Lung Cancer</value>
<value>Vinorelbine / CISplatin. Advanced NSCLC</value>
<value>CISplatin &amp; Vinorelbine with CONCURRENT RT. Non-Small Cell Lung Cancer</value>
<value>Gemcitabine / CISplatin. Non-Small Cell Lung Cancer</value>
<value>CISplatin/etoposide (po). Small Cell Lung Cancer</value>
<value>Pemetrexed / CISplatin. Mesothelioma.</value>
<value>Etoposide (Days 1-5)/CISplatin (Days 1 &amp; 8) with concurrent RT. Pancoast Tumor</value>
<value>DOXOrubicin/CISplatin/cyclophosphamide (PAC). Thymic Malignancy</value>
<value>CISplatin/DOXOrubicin/vinCRIStine/cyclophosphamide. Thymoma</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes></AdditionalNotes>
<BackgroundInformation></BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus></AHSFormularyStatus>
<HighAlert></HighAlert>
</drug>